TP53 and neoplasm: Chemotherapy response assays show that WTPDX phenocopy predicted tumor response by capturing the treatment resistance of TP53 mutant unfavorable histology WT and the relative sensitivity of favorable histology disease to 2-drug or 3-drug combination therapy with vincristine, actinomycin-D, and doxorubicin.